Summit Therapeutics (NASDAQ: SMMT) reported a narrower-than-expected loss for the first quarter of 2019 while revenues missed estimates. The stock was inactive
Summit Therapeutics reports loss of $0.04 per share for Q1
Categories
Health Care
CymaBay Therapeutics stock drops to 2-year low after bitter NASH study data
CymaBay Therapeutics (NASDAQ: CBAY) stock fell to a two-year low of $4.82 on Tuesday after disappointing nonalcoholic steatohepatitis (NASH) trial data. The
Advaxis’ revenue declines in Q2 as Amgen terminaties collaboration agreement
Advaxis (NASDAQ: ADXS) reported that Q2 revenue decreased to $1.2 million from $1.7 million in the prior year quarter. The 32% decline
Earnings preview: Advaxis stock treading near an all-time low ahead of Q2 results
Late-stage biotech firm Advaxis, Inc. (NASDAQ: ADXS) is scheduled to report second-quarter financial results on June 10, Monday, after the closing bell.
Tilray stock heads downward on doubts of cannabis risks
Tilray (NASDAQ: TLRY) stock has fallen over 47% in the year so far. The stock has been on a downward trend since
What’s in store for top pharma stocks this year
The stocks of leading pharmaceutical firms shifted to growth mode this year after winding up 2018 on a low note, in line
CVS’ stock gains as company lays out growth strategy
CVS Health’s (NYSE: CVS) shares were up 3.2% in afternoon hours as the company outlined its growth strategy and reaffirmed guidance at
WeedMD posts wider loss in Q1 but revenue soars 192%
Medical-grade cannabis producer WeedMD Inc. reported a wider loss in the first quarter of 2019 due to higher costs and expenses despite
Veeva Systems reports stellar Q1 earnings, outlook beat estimates
Veeva Systems (NYSE: VEEV) reported yet another solid earnings beating analyst estimates. The company also raised its full-year outlook and gave guidance
Looming opioid epidemic calls for stricter drug regulation
Though the healthcare industry is slowly waking up to the hazards of opioid-based prescription drugs, their sale continues unabated across all markets,
Soliton spikes over 50% on its decision to proceed with cellulite trials
Shares of Soliton Inc. (NASDAQ: SOLY) jumped over 50% during the morning trade on Wednesday after the medical device company said in
Charlotte’s Web Holdings retains full-year outlook; to delist from CSE
Charlotte’s Web Holdings (CSE: CWEB; OTCQX: CWBHF) first-quarter results came in line with the preliminary guidance provided earlier this month. However, it
Earnings Preview: Charlotte’s Web to report solid Q1 results aided by multiple tailwinds
Charlotte's Web Holdings (CSE: CWEB; OTCQX: CWBHF) is planning to report its first-quarter results tomorrow after the bell. The company is expected
Novartis’ one-time gene therapy for spinal muscular atrophy gets FDA nod
Picture Courtesy: Novartis Zolgensma, a gene-based treatment from Novartis (NYSE: NVS) for the treatment of spinal muscular atrophy that affects newborns, received
Centene stock spikes as activist investor Third Point pushes for its sale
Shares of Centene Corp (NYSE: CNC) shot up over 3% on average volume on Friday, after it was revealed that activist investor
Medtronic tops expectations on Q4 results
Medtronic plc (NYSE: MDT) reported revenue and earnings for the fourth quarter of 2019 that topped market expectations. Shares rose 2.4% in
Affimed’s stock tanks as company announces termination of cancer program
Affimed NV (NASDAQ: AFMD) reported first-quarter 2019 earnings results and announced its plans to terminate its cancer program while focusing its R&D
Canopy Growth names Constellation Brands veteran as acting CFO
Image by Rex Medlen from Pixabay Shares of Canopy Growth Corporation (NYSE: CGC) gained over 2% on Tuesday after the cannabis giant
Medtronic to announce Q4 results amidst pacemaker crisis
Medtronic (NYSE: MDT) is scheduled to report fourth-quarter 2019 financial results on Thursday, May 23, before the regular trading hours. The Dublin-based
Bio-Path’s stock tanks as company delivers loss for Q1
Bio-Path Holdings Inc.’s (NASDAQ: BPTH) shares were down 3.2% in morning hours on Thursday after the company reported its first quarter 2019
Titan Pharmaceuticals posts wider-than-expected Q1 loss
Titan Pharmaceuticals (TTNP) reported a wider loss in the first quarter of 2019 due to lower revenues and higher operating expenses. The